Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy.
Mutations in myelin genes cause inherited peripheral neuropathies that range in severity from adult-onset Charcot-Marie-Tooth disease type 1 to childhood-onset Dejerine-Sottas neuropathy and congenital hypomyelinating neuropathy. Many myelin gene mutants that cause severe disease, such as those in the myelin protein zero gene (MPZ) and the peripheral myelin protein 22 gene (PMP22), appear to make aberrant proteins that accumulate primarily within the endoplasmic reticulum (ER), resulting in Schwann cell death by apoptosis and, subsequently, peripheral neuropathy. We previously showed that curcumin supplementation could abrogate ER retention and aggregation-induced apoptosis associated with neuropathy-causing MPZ mutants. We now show reduced apoptosis after curcumin treatment of cells in tissue culture that express PMP22 mutants. Furthermore, we demonstrate that oral administration of curcumin partially mitigates the severe neuropathy phenotype of the Trembler-J mouse model in a dose-dependent manner. Administration of curcumin significantly decreases the percentage of apoptotic Schwann cells and results in increased number and size of myelinated axons in sciatic nerves, leading to improved motor performance. Our findings indicate that curcumin treatment is sufficient to relieve the toxic effect of mutant aggregation-induced apoptosis and improves the neuropathologic phenotype in an animal model of human neuropathy, suggesting a potential therapeutic role in selected forms of inherited peripheral neuropathies.
Khajavi
Mehrdad
M
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Shiga
Kensuke
K
Wiszniewski
Wojciech
W
He
Feng
F
Shaw
Chad A
CA
Yan
Jiong
J
Wensel
Theodore G
TG
Snipes
G Jackson
GJ
Lupski
James R
JR
D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D003474:Curcumin / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006367:HeLa Cells; D015417:Hereditary Sensory and Motor Neuropathy / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D051379:Mice; D008817:Mice, Mutant Strains; D009185:Myelin Proteins / Q000235:genetics*; D012583:Schwann Cells / Q000187:drug effects*; D012584:Sciatic Nerve / Q000187:drug effects / Q000473:pathology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009185:Myelin Proteins; C073687:PMP22 protein, human; D003474:Curcumin
Hum Mol Genet. 2000 Jul 22;9(12):1865-71
10915775
Curr Opin Neurobiol. 2000 Oct;10(5):552-7
11084316
Annu Rev Neurosci. 2000;23:89-125
10845060
J Cell Biol. 1998 Feb 23;140(4):925-34
9472043
J Cell Biol. 1992 Apr;117(1):225-38
1556154
Nat Med. 2004 Apr;10(4):396-401
15034573
J Neurosci. 1997 Jun 1;17(11):4190-200
9151736
J Neurocytol. 1988 Feb;17(1):55-62
3418356
Ann N Y Acad Sci. 1999 Sep 14;883:143-51
10586240
Neurobiol Dis. 2006 Apr;22(1):153-64
16326107
Clin Genet. 1974;6(2):98-118
4430158
Nat Rev Neurosci. 2005 Jan;6(1):11-22
15611723
Cell. 1991 Jul 26;66(2):219-32
1677316
J Neurosci Res. 2005 Sep 15;81(6):857-64
16041800
Science. 2004 Apr 23;304(5670):600-2
15105504
Hum Mol Genet. 2004 Nov 1;13(21):2581-94
15367490
J Biol Chem. 1993 May 15;268(14):10372-9
8486695
Neurobiol Dis. 1999 Feb;6(1):1-14
10078969
Neurogenetics. 2005 Feb;6(1):1-16
15627202
FASEB J. 2004 Oct;18(13):1553-5
15319364
Am J Hum Genet. 2005 Nov;77(5):841-50
16252242
Nat Med. 2003 Dec;9(12):1533-7
14608378
Cell. 1993 Jan 15;72(1):143-51
8422677
J Anat. 1997 Oct;191 ( Pt 3):321-36
9418989
J Biol Chem. 2004 Sep 24;279(39):40629-33
15280357
Neurobiol Dis. 2000 Dec;7(6 Pt B):561-73
11114256
J Neuropathol Exp Neurol. 1996 Mar;55(3):290-9
8786387
Nat Genet. 1992 Dec;2(4):288-91
1303281
FEBS Lett. 2002 Sep 25;528(1-3):17-22
12297272
Neuromolecular Med. 2006;8(1-2):1-2
16775363
Muscle Nerve. 1997 Jan;20(1):97-9
8995589
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4382-6
1374899
Anticancer Res. 2001 Jul-Aug;21(4B):2895-900
11712783
Brain. 2001 Nov;124(Pt 11):2177-87
11673320
J Neurosci Res. 1996 May 15;44(4):328-37
8739151
Hum Mol Genet. 1994 Feb;3(2):223-8
8004087
Nat Genet. 1992 Apr;1(1):29-33
1301995
Ann N Y Acad Sci. 1999 Sep 14;883:91-108
10586235
Mutat Res. 2004 Nov 2;555(1-2):53-64
15476851
J Biol Chem. 2005 Feb 18;280(7):5892-901
15590663
Neuromuscul Disord. 1991;1(2):93-7
1822787
Biochem Mol Biol Int. 1996 Feb;38(2):393-99
8850535
Nature. 1992 Mar 19;356(6366):241-4
1552943
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9852-7
12119418